Peginterferon alpha-2b
Synonym(s)
alfa-2b; alpha-2b; Interferon; Interferon alpha-2b pegylated; peginterferon-alpha-2b; Peginterferon alpha-2b; pegylated; pegylated alpha-interferon-2b; pegylated IFN α-2b; pegylated IFN-α-2b; α-2b
DefinitionThis section has been translated automatically.
Synthetic, recombinant interferon alpha derivative. Coupling to polyethylene glycol (PEG) results in delayed degradation and prolonged residence time in the organism (see pegylation below).
IndicationThis section has been translated automatically.
Chronic hepatitis C in case of elevated transaminases and detectable HCV RNA in serum or anti-HCV positivity, not in patients with compensated cirrhosis of the liver.
Pregnancy/nursing periodThis section has been translated automatically.
Contraindicated.
Dosage and method of useThis section has been translated automatically.
- monotherapy (preferably in case of intolerance to ribavirin): 0,5 or 1,0 μg/kg bw/week s.c.
- Combination therapy with ribavirin: 1.5 μg/kg bw/week s.c. in combination with ribavirin (e.g. rebetol): 800 mg/day for patients < 65 kg bw p.o., 1000 mg/day for patients 65-85 kg bw, 1200 mg/day for patients > 85 kg bw.
Remember! Preferably peginterferon/ribavirin combination therapy in naive patients as well as in patients who have responded to interferon alpha monotherapy (with normalization of ALT values at the end of treatment) but have relapsed.
Undesirable effectsThis section has been translated automatically.
Frequently flu-like general symptoms (fever, fatigue, chills, headaches, myalgia, sweating), reactions at the injection site (erythema) Rare maculopapular drug exanthema.
InteractionsThis section has been translated automatically.
Increase of the plasma level of theophylline.
PreparationsThis section has been translated automatically.
Pegintron